Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.

[1]  T. Shimoda,et al.  Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey. , 2018, Allergology international : official journal of the Japanese Society of Allergology.

[2]  Y. Gon,et al.  Role of airway epithelial barrier dysfunction in pathogenesis of asthma. , 2018, Allergology international : official journal of the Japanese Society of Allergology.

[3]  Matthew C. Altman,et al.  Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis. , 2017, The journal of allergy and clinical immunology. In practice.

[4]  A. Peters,et al.  Monoclonal Antibody Therapy in Sinonasal Disease , 2017, American journal of rhinology & allergy.

[5]  Wei-jun Cao,et al.  Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature. , 2017, Respiratory medicine.

[6]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[7]  R. Moss.  Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis , 2013, European Respiratory Journal.

[8]  C. Bachert,et al.  Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. , 2011, The Journal of allergy and clinical immunology.

[9]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[10]  R. Patterson,et al.  Allergic bronchopulmonary aspergillosis: staging as an aid to management. , 1982, Annals of internal medicine.